Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 342.47
ABAX's Cash to Debt is ranked higher than
71% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.19 vs. ABAX: 342.47 )
Ranked among companies with meaningful Cash to Debt only.
ABAX' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 227.05 Max: No Debt
Current: 342.47
Equity to Asset 0.87
ABAX's Equity to Asset is ranked higher than
91% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. ABAX: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
ABAX' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.86 Max: 0.9
Current: 0.87
0.51
0.9
Interest Coverage 69.50
ABAX's Interest Coverage is ranked higher than
53% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.98 vs. ABAX: 69.50 )
Ranked among companies with meaningful Interest Coverage only.
ABAX' s Interest Coverage Range Over the Past 10 Years
Min: 27.18  Med: 9999.00 Max: 9999.99
Current: 69.5
27.18
9999.99
F-Score: 5
Z-Score: 19.98
M-Score: -2.13
WACC vs ROIC
7.89%
30.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 21.18
ABAX's Operating margin (%) is ranked higher than
88% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.67 vs. ABAX: 21.18 )
Ranked among companies with meaningful Operating margin (%) only.
ABAX' s Operating margin (%) Range Over the Past 10 Years
Min: 12.1  Med: 16.77 Max: 22.65
Current: 21.18
12.1
22.65
Net-margin (%) 14.45
ABAX's Net-margin (%) is ranked higher than
86% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.03 vs. ABAX: 14.45 )
Ranked among companies with meaningful Net-margin (%) only.
ABAX' s Net-margin (%) Range Over the Past 10 Years
Min: 8.25  Med: 11.53 Max: 14.76
Current: 14.45
8.25
14.76
ROE (%) 13.71
ABAX's ROE (%) is ranked higher than
81% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.56 vs. ABAX: 13.71 )
Ranked among companies with meaningful ROE (%) only.
ABAX' s ROE (%) Range Over the Past 10 Years
Min: 7.67  Med: 11.53 Max: 16.35
Current: 13.71
7.67
16.35
ROA (%) 11.78
ABAX's ROA (%) is ranked higher than
90% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.78 vs. ABAX: 11.78 )
Ranked among companies with meaningful ROA (%) only.
ABAX' s ROA (%) Range Over the Past 10 Years
Min: 6.77  Med: 10.01 Max: 14.32
Current: 11.78
6.77
14.32
ROC (Joel Greenblatt) (%) 62.26
ABAX's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. ABAX: 62.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABAX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 27.72  Med: 42.82 Max: 64.9
Current: 62.26
27.72
64.9
Revenue Growth (3Y)(%) 4.80
ABAX's Revenue Growth (3Y)(%) is ranked higher than
53% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.90 vs. ABAX: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABAX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.8  Med: 13.80 Max: 32.8
Current: 4.8
4.8
32.8
EBITDA Growth (3Y)(%) 2.30
ABAX's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. ABAX: 2.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABAX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.9  Med: 21.70 Max: 222.4
Current: 2.3
1.9
222.4
EPS Growth (3Y)(%) 3.50
ABAX's EPS Growth (3Y)(%) is ranked higher than
57% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. ABAX: 3.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABAX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.2  Med: 5.95 Max: 143.8
Current: 3.5
-59.2
143.8
» ABAX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ABAX Guru Trades in Q2 2015

Steven Cohen 2,800 sh (New)
Paul Tudor Jones 7,880 sh (New)
Jim Simons 4,500 sh (New)
Joel Greenblatt 156,809 sh (+426.63%)
PRIMECAP Management 2,345,000 sh (+16.02%)
Columbia Wanger 848,025 sh (+15.25%)
» More
Q3 2015

ABAX Guru Trades in Q3 2015

Steven Cohen 67,500 sh (+2310.71%)
Jim Simons 105,595 sh (+2246.56%)
Columbia Wanger 855,949 sh (+0.93%)
PRIMECAP Management 2,345,000 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt 127,866 sh (-18.46%)
» More
Q4 2015

ABAX Guru Trades in Q4 2015

Jim Simons 214,671 sh (+103.30%)
PRIMECAP Management 2,346,000 sh (+0.04%)
Joel Greenblatt Sold Out
Steven Cohen 51,200 sh (-24.15%)
Columbia Wanger 640,699 sh (-25.15%)
» More
Q1 2016

ABAX Guru Trades in Q1 2016

Paul Tudor Jones 9,600 sh (New)
PRIMECAP Management 2,347,500 sh (+0.06%)
Steven Cohen Sold Out
Columbia Wanger Sold Out
Jim Simons 204,519 sh (-4.73%)
» More
» Details

Insider Trades

Latest Guru Trades with ABAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:ALOG, NAS:AFFX, NAS:EXAS, NAS:GHDX, NAS:VIVO, NAS:AXDX, NAS:KANG, NAS:NTRA, NAS:FMI, NAS:NEO, OTCPK:EPLYF, NAS:NVDQ, NAS:QDEL, NAS:BEAT, NAS:NRCIA, AMEX:SENS, AMEX:ONVO, NAS:SRDX, NYSE:NVTA, NAS:FLDM » details
Traded in other countries:AXS.Germany,
Abaxis Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements.

Abaxis Inc is a California corporation and was incorporated in 1989. The Company is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. Its products and services include point-of-care diagnostic instruments and consumables used in the medical market and point-of-care diagnostic instruments and consumables used in the veterinary market. The Company manages its business in two reportable business segments, the medical market and the veterinary market, which are based on the diagnostic products sold and services provided by market and customer group. For products that it sells that are not specifically identified to any particular business segment, it categorizes the revenue as Other. The Company's products sold to the medical market are used by medical specialties requiring real time results to enable rapid clinical decisions in the area of human diagnostics. Its point-of-care products in the medical market are comprised of its Piccolo chemistry analyzers and consumable products. In the veterinary market, its VetScan products serves a customer group consisting of companion animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies and private research laboratories. Its product and service offerings in the veterinary market include VetScan Point-of-Care Blood Chemistry Instruments, VetScan Profiles, Hematology Instruments and Consumables, VSpro Specialty Analyzers and Consumables, i-STAT Instruments and Consumables, Rapid Tests, and Abaxis Veterinary Reference Laboratories services. Its Other segment include sale of products using its patented Orbos Discrete Lyophilization Process (the Orbos process) to companies for other applications. The Orbos process involves flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The Orbos beads are stable in dry form and dissolve rapidly in aqueous solutions. The dry reagents used in its reagent discs are produced using the Orbos process. This process allows the production of a precise amount of active chemical ingredient in the form of a soluble bead. The Company's competitors in the point-of-care human medical diagnostic market are Inverness Medical Switzerland GmbH, now known as Alere Switzerland GmbH ("Alere"), Alfa Wassermann S.P.A., Johnson & Johnson, Ortho-Clinical Diagnostics, Inc. and F. Hoffmann-La Roche Ltd. The Company's Piccolo products are in vitro diagnostic medical devices subject to regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act (FDCA).

Ratios

vs
industry
vs
history
P/E(ttm) 31.63
ABAX's P/E(ttm) is ranked lower than
53% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.99 vs. ABAX: 31.63 )
Ranked among companies with meaningful P/E(ttm) only.
ABAX' s P/E(ttm) Range Over the Past 10 Years
Min: 20.82  Med: 44.62 Max: 75.93
Current: 31.63
20.82
75.93
Forward P/E 31.06
ABAX's Forward P/E is ranked lower than
74% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.76 vs. ABAX: 31.06 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 32.34
ABAX's PE(NRI) is ranked lower than
55% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.19 vs. ABAX: 32.34 )
Ranked among companies with meaningful PE(NRI) only.
ABAX' s PE(NRI) Range Over the Past 10 Years
Min: 20.75  Med: 45.64 Max: 74.58
Current: 32.34
20.75
74.58
Price/Owner Earnings (ttm) 76.48
ABAX's Price/Owner Earnings (ttm) is ranked lower than
82% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.99 vs. ABAX: 76.48 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABAX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 16.03  Med: 53.46 Max: 352.63
Current: 76.48
16.03
352.63
P/B 4.17
ABAX's P/B is ranked lower than
62% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.23 vs. ABAX: 4.17 )
Ranked among companies with meaningful P/B only.
ABAX' s P/B Range Over the Past 10 Years
Min: 2.19  Med: 4.65 Max: 8.07
Current: 4.17
2.19
8.07
P/S 4.61
ABAX's P/S is ranked lower than
64% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ABAX: 4.61 )
Ranked among companies with meaningful P/S only.
ABAX' s P/S Range Over the Past 10 Years
Min: 2.48  Med: 5.03 Max: 8.56
Current: 4.61
2.48
8.56
PFCF 44.01
ABAX's PFCF is ranked lower than
69% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.66 vs. ABAX: 44.01 )
Ranked among companies with meaningful PFCF only.
ABAX' s PFCF Range Over the Past 10 Years
Min: 21.4  Med: 46.23 Max: 101.82
Current: 44.01
21.4
101.82
POCF 35.84
ABAX's POCF is ranked lower than
86% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.46 vs. ABAX: 35.84 )
Ranked among companies with meaningful POCF only.
ABAX' s POCF Range Over the Past 10 Years
Min: 17.14  Med: 34.37 Max: 79.01
Current: 35.84
17.14
79.01
EV-to-EBIT 18.56
ABAX's EV-to-EBIT is ranked lower than
52% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.18 vs. ABAX: 18.56 )
Ranked among companies with meaningful EV-to-EBIT only.
ABAX' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.6  Med: 27.00 Max: 48.1
Current: 18.56
10.6
48.1
EV-to-EBITDA 16.21
ABAX's EV-to-EBITDA is ranked lower than
62% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.58 vs. ABAX: 16.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.7  Med: 22.20 Max: 40.5
Current: 16.21
8.7
40.5
PEG 2.44
ABAX's PEG is ranked higher than
51% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. ABAX: 2.44 )
Ranked among companies with meaningful PEG only.
ABAX' s PEG Range Over the Past 10 Years
Min: 0.7  Med: 2.31 Max: 11.8
Current: 2.44
0.7
11.8
Shiller P/E 52.97
ABAX's Shiller P/E is ranked lower than
73% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.88 vs. ABAX: 52.97 )
Ranked among companies with meaningful Shiller P/E only.
ABAX' s Shiller P/E Range Over the Past 10 Years
Min: 42.35  Med: 64.11 Max: 467.2
Current: 52.97
42.35
467.2
Current Ratio 7.27
ABAX's Current Ratio is ranked higher than
85% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.85 vs. ABAX: 7.27 )
Ranked among companies with meaningful Current Ratio only.
ABAX' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 5.39 Max: 9.82
Current: 7.27
1.67
9.82
Quick Ratio 6.07
ABAX's Quick Ratio is ranked higher than
84% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ABAX: 6.07 )
Ranked among companies with meaningful Quick Ratio only.
ABAX' s Quick Ratio Range Over the Past 10 Years
Min: 1.19  Med: 4.45 Max: 8.45
Current: 6.07
1.19
8.45
Days Inventory 133.50
ABAX's Days Inventory is ranked lower than
68% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.32 vs. ABAX: 133.50 )
Ranked among companies with meaningful Days Inventory only.
ABAX' s Days Inventory Range Over the Past 10 Years
Min: 96.42  Med: 119.01 Max: 136.06
Current: 133.5
96.42
136.06
Days Sales Outstanding 58.61
ABAX's Days Sales Outstanding is ranked higher than
55% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. ABAX: 58.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.27  Med: 71.25 Max: 78.49
Current: 58.61
52.27
78.49
Days Payable 27.83
ABAX's Days Payable is ranked lower than
79% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.90 vs. ABAX: 27.83 )
Ranked among companies with meaningful Days Payable only.
ABAX' s Days Payable Range Over the Past 10 Years
Min: 22.72  Med: 33.18 Max: 65.46
Current: 27.83
22.72
65.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.03
ABAX's Dividend Yield is ranked lower than
59% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.25 vs. ABAX: 1.03 )
Ranked among companies with meaningful Dividend Yield only.
ABAX' s Dividend Yield Range Over the Past 10 Years
Min: 0.21  Med: 0.77 Max: 1.11
Current: 1.03
0.21
1.11
Dividend Payout 0.32
ABAX's Dividend Payout is ranked higher than
50% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. ABAX: 0.32 )
Ranked among companies with meaningful Dividend Payout only.
ABAX' s Dividend Payout Range Over the Past 10 Years
Min: 0.32  Med: 0.38 Max: 0.44
Current: 0.32
0.32
0.44
Forward Dividend Yield 1.07
ABAX's Forward Dividend Yield is ranked lower than
59% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.25 vs. ABAX: 1.07 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.03
ABAX's Yield on cost (5-Year) is ranked lower than
59% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.43 vs. ABAX: 1.03 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABAX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.21  Med: 0.77 Max: 1.11
Current: 1.03
0.21
1.11
3-Year Average Share Buyback Ratio -0.40
ABAX's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.00 vs. ABAX: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.7  Med: -2.80 Max: 0.4
Current: -0.4
-9.7
0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.39
ABAX's Price/Net Cash is ranked lower than
58% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.35 vs. ABAX: 10.39 )
Ranked among companies with meaningful Price/Net Cash only.
ABAX' s Price/Net Cash Range Over the Past 10 Years
Min: 6.71  Med: 14.66 Max: 190.5
Current: 10.39
6.71
190.5
Price/Net Current Asset Value 5.57
ABAX's Price/Net Current Asset Value is ranked higher than
58% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.70 vs. ABAX: 5.57 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ABAX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.79  Med: 7.72 Max: 41.9
Current: 5.57
3.79
41.9
Price/Tangible Book 4.19
ABAX's Price/Tangible Book is ranked higher than
53% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.69 vs. ABAX: 4.19 )
Ranked among companies with meaningful Price/Tangible Book only.
ABAX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.88  Med: 4.93 Max: 18.18
Current: 4.19
2.88
18.18
Price/Projected FCF 2.08
ABAX's Price/Projected FCF is ranked higher than
50% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. ABAX: 2.08 )
Ranked among companies with meaningful Price/Projected FCF only.
ABAX' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.85  Med: 2.87 Max: 15.28
Current: 2.08
1.85
15.28
Price/DCF (Earnings Based) 2.04
ABAX's Price/DCF (Earnings Based) is ranked lower than
64% of the 14 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. ABAX: 2.04 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.91
ABAX's Price/Median PS Value is ranked higher than
50% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. ABAX: 0.91 )
Ranked among companies with meaningful Price/Median PS Value only.
ABAX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 0.93 Max: 1.69
Current: 0.91
0.32
1.69
Price/Peter Lynch Fair Value 2.24
ABAX's Price/Peter Lynch Fair Value is ranked lower than
52% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. ABAX: 2.24 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ABAX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.28  Med: 2.42 Max: 8.05
Current: 2.24
1.28
8.05
Price/Graham Number 2.46
ABAX's Price/Graham Number is ranked higher than
62% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.18 vs. ABAX: 2.46 )
Ranked among companies with meaningful Price/Graham Number only.
ABAX' s Price/Graham Number Range Over the Past 10 Years
Min: 2.1  Med: 3.00 Max: 11.23
Current: 2.46
2.1
11.23
Earnings Yield (Greenblatt) (%) 5.40
ABAX's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. ABAX: 5.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABAX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.1  Med: 3.70 Max: 9.5
Current: 5.4
2.1
9.5
Forward Rate of Return (Yacktman) (%) 16.75
ABAX's Forward Rate of Return (Yacktman) (%) is ranked higher than
73% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.84 vs. ABAX: 16.75 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABAX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 6.9  Med: 17.60 Max: 44.4
Current: 16.75
6.9
44.4

More Statistics

Revenue (TTM) (Mil) $218.9
EPS (TTM) $ 1.39
Beta0.82
Short Percentage of Float16.64%
52-Week Range $37.71 - 58.15
Shares Outstanding (Mil)22.50

Analyst Estimate

Mar17
Revenue (Mil $)
EPS ($) 1.44
EPS w/o NRI ($) 1.44
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for ABAX

Headlines

Articles On GuruFocus.com
PRIMECAP Adds to Three Stakes in Portfolio Jul 07 2015 
Distribution: A Potentially Under-appreciated Moat Jun 08 2015 
ABAXIS Inc. (ABAX) COO Donald Peter Wood sells 6,460 Shares Mar 08 2011 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 35,000 Shares Dec 10 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 96,000 Shares Dec 08 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 66,029 Shares Dec 07 2010 

More From Other Websites
Unleashed: A Wave Of Pet-Friendly Services & Innovations Jun 24 2016
ABAXIS, Inc. – Value Analysis (NASDAQ:ABAX) : June 21, 2016 Jun 21 2016
ABAXIS, Inc. breached its 50 day moving average in a Bearish Manner : ABAX-US : June 20, 2016 Jun 20 2016
Abaxis Global Diagnostics and AAHA Develop Preventive Care Testing Initiative Jun 06 2016
Abaxis (ABAX): Solid Veterinary Show Despite Global Hiccups Jun 06 2016
ABAXIS INC Financials Jun 04 2016
Abaxis, Inc. to Present at the Jefferies 2016 Global Healthcare Conference Jun 01 2016
Abaxis, Inc. to Present at the Jefferies 2016 Global Healthcare Conference Jun 01 2016
ABAXIS INC Files SEC form 10-K, Annual Report May 31 2016
New Strong Sell Stocks for May 31st May 31 2016
Abaxis, Inc. to Present at the Stifel 2016 Dental & Veterinary Conference May 25 2016
Abaxis (ABAX) Posts Solid Q4 amid International Headwind May 25 2016
ETF’s with exposure to ABAXIS, Inc. : May 24, 2016 May 24 2016
ABAXIS, Inc. breached its 50 day moving average in a Bullish Manner : ABAX-US : May 23, 2016 May 23 2016
New Strong Sell Stocks for May 12th May 12 2016
New Strong Sell Stocks for May 6th May 06 2016
ABAXIS, Inc. :ABAX-US: Earnings Analysis: Q4, 2016 By the Numbers May 03 2016
Abaxis (ABAX) Q4 Earnings Beat Estimates; Dividend Raised Apr 29 2016
Abaxis tops Street 4Q forecasts Apr 28 2016
Abaxis tops Street 4Q forecasts Apr 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)